The role of upregulated miR-375 expression in breast cancer: an in vitro and in silico study

Publication date: Available online 18 November 2019Source: Pathology - Research and PracticeAuthor(s): Wei Tang, Guo-Sheng Li, Jian-Di Li, Wen-Ya Pan, Qi Shi, Dan-Dan Xiong, Chao-Hua Mo, Jing-Jing Zeng, Gang Chen, Zhen-Bo Feng, Su-Ning Huang, Min-Hua RongAbstractBreast cancer (BC) is the most common cancer worldwide. However, the expression and potential mechanism of miR-375 in BC are still controversial. We first collected microRNA chips and microRNA sequencing data from multiple databases for analyzing the expression level of miR-375, and further exploring the target genes and underlying molecular mechanism in BC. miR-375 in BC was predominantly overexpressed compared with that in normal breast tissues (pooled standard mean difference [SMD] = 0.49; 95% confidence interval [CI]: 0.24–0.73, p <  0.0001). Meanwhile, the overall pooled area under the curve (AUC) in the summary receiver operating characteristic (SROC) of miR-375 was 0.83 (95%CI=0.79-0.86) based on 2928 cases of BC patients and 816 cases of controls, while the diagnostic positive likelihood ratio (DLR) positive and the DLR negative value were 3.90 (95%CI=2.46-6.19) and 0.39 (95%CI=0.28-0.54), respectively. The hazard ratios (HRs) were 1.29 (95%CI= 1.04-1.6, P=0.02) and 1.23 (95%CI= 0.89-1.7, P=0.22) for the cohorts of METABRIC and The Cancer Genome Atlas (TCGA). In vitro study demonstrated that miR-375 inhibitor could suppress the cell growth and induce apoptosis of BC cells. A total of 107 overlapp...
Source: Pathology Research and Practice - Category: Pathology Source Type: research